NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies

Author: Dent S.   Gelmon K.   Chi K.   Jonker D.   Wainman N.   Capier C.   Chen E.   Lyons J.   Seymour L.  

Publisher: Springer Publishing Company

ISSN: 0167-6997

Source: Investigational New Drugs, Vol.31, Iss.6, 2013-12, pp. : 1522-1529

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content